Sort   by:  
 Page size 

Schizophrenia is a severe psychiatric disorder impacting roughly 1% of individuals. The effectiveness of antipsychotic therapy greatly varies, with around 30% of patients categorised as treatment-resistant (TRS). TRS is characterised by a lack of response to at least two clinical trials invo...

2025-10-01 | MTBLS12709 | MetaboLights

Beyond motor neuron degeneration, homozygous mutations in the survival motor neuron 1 (SMN1) gene cause multiorgan and metabolic defects in patients with spinal muscular atrophy (SMA). However, the precise biochemical features of these alterations and the age of onset in the brain and peripheral ...

2023-11-27 | MTBLS8784 | MetaboLights

Rationale: Sex and type of Parkinson's disease (PD) significantly influence onset age, clinical manifestations, treatment response, disease progression and life expectancy. However, the selective influence of idiopathic and familial forms of PD in disrupting blood metabolome profiles across gende...

2025-09-03 | MTBLS11187 | MetaboLights

Background: Sex and genetic background have an impact on Parkinson’s disease (PD) insurgence, but the comprehension of how these factors affect the circulating profile of PD patients is still an aim of study.

Objectives: In this study we aimed to investigate whether genetic background and ...

2026-06-26 | MTBLS12753 | MetaboLights

Background: Recent findings from our group indicate that sex differences in Parkinson's disease (PD) patients with idiopathic conditions or carrying pathogenic mutations significantly influence the blood occurrence of D and L-amino acids, lipids, antioxidants, and energy-related metabolites when ...

2026-06-26 | MTBLS12746 | MetaboLights
Sort   by:  
 Page size